---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-073587"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2023-12-28T23:59:59+00:00"
generated_at: "2026-06-07T06:21:34.366174+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Clearside Biomedical waives $12.5M milestone payment, releases escrow to HCR

## Summary
- Subsidiary Clearside Royalty waived all rights to $12.5M milestone payment tied to XIPERE sales.
- Payment held in escrow under 2022 Purchase Agreement; released to Healthcare Royalty Partners IV.
- First Milestone Event required milestone by March 31, 2024; waiver eliminates potential payment.
- Escrow agreement terminated upon release of funds to purchaser.

## SEC filing metadata
- accession: 0000950170-23-073587
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2023-12-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017023073587/0000950170-23-073587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017023073587/clsd-20231222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-073587
- JSON: https://secwatch.observer/filing/0000950170-23-073587.json
- Plain text: https://secwatch.observer/filing/0000950170-23-073587.txt

## Key facts
- Material Agreements
  Clearside Biomedical, Inc. amended Letter Agreement with Healthcare Royalty Partners IV, L.P., HCR Clearside SPV, LLC valued at $12.5 million milestone payment (effective 2023-12-22).
  - Action: amendment
  - Agreement: asset purchase
  - Counterparty: Healthcare Royalty Partners IV, L.P., HCR Clearside SPV, LLC
  - Value: $12.5 million milestone payment
  - Effective: 2023-12-22
  source text: On December 22, 2023, Clearside Biomedical, Inc., through its wholly owned subsidiary Clearside Royalty LLC (" Royalty Sub "), entered into a letter agreement (the " Letter Agreement ") with Healthcare Royalty Partners IV, L.P. (" HCR ") and HCR Clearside SPV, LLC (as assignee of HCR Collateral Management, LLC) (" Agent ") amending that certain Purchase and Sale Agreement, dated as of August 8, 2022 (the " Purchase Agreement "), by and among Royalty Sub, HCR and Agent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017023073587/0000950170-23-073587-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.